Attitudes to home artificial nutrition (HAN) in cancer vary greatly from country to country. A 6-year prospective survey of the practice of HAN in advanced cancer patients applied by a hospital-at-home programme in an Italian health district was performed to estimate the utilization rate, to evaluate efficacy in preventing death from cachexia, maintaining patients at home without burdens and distress and improving patients' performance status, and to obtain information about costs. Patients were eligible for HAN when all the following were present: hypophagia; life expectancy 6 weeks or more, suitable patient and family circumstances; and verbal informed consent.
INTRODUCTION
Attitudes to home artificial nutrition (HAN) in advanced non-curable cancer differ between countriesl. A European multicentre survey2 conducted in 1993 showed that the proportion of patients with a diagnosis of cancer receiving home parenteral nutrition (HPN) varied from 9% in the UK to 21% in France and 67% in Italy. National home enteral nutrition (HEN) registers indicate that cancer is the diagnosis in 20% of HAN patients in the Netherlands3, 30% in the UK4, 67% in Italy5 and 70% in Switzerland6. In the USA malignancy is the most frequent indication for both HPN (42%) and HEN (43%)7.
The basis of these different attitudes has not yet been clarified, but the main factors seem to be ethical and 'First Medical Clinic, Department of Internal Medicine and Gastroenterology, 2Division of Medical Oncology, S. Orsola-Malpighi Hospital, Via Massarenti 9, 40138 Bologna, University of Bologna; 3Associazione Nazionale Tumori, Bologna, Italy Correspondence to: Dr L Pironi economic8. Advocates of HAN say that it avoids death from cancer cachexia, improves quality of life by allowing the patient to stay with family and reduces hospital admissions for nutritional support, thus cutting health care costs 8. However, others point out that HAN may prolong suffering in patients with poorly controlled pain, increase distress by inducing complications, and reduce the quality of life by generating anxiety over management of this sophisticated therapy at home9. Furthermore, ethical and financial constraints may mean that priority should go to other health needs. No study has defined the cost-benefit and the cost-effectiveness of these different approaches10.
In the Bologna health district (3.076 sq km, and 811 596 inhabitants), home care of advanced cancer patients is provided mainly by a hospital-at-home programme supported by a private non-profit-making organization, Associazione Nazionale Tumori (ANT). ANT consists of physicians and nurses supported by voluntary work, grants and donations 1. Bologna health district previously lacked a 597 HAN programme for advanced cancer patients, and in 1990 we set up an ANT-supported project, prospectively auditing our practice. Our aims were to estimate the utilization rate of HAN; evaluate the efficacy of HAN in preventing death from cachexia, maintaining patients at home without burdens and distress to patient and family and in improving patients' performance status; and obtain information about cost-determining items of HAN.
METHODS

Patient selection
The study started on 1 July 1990. Data on patients entered on HAN up to 30 June 1996 and followed up to 31 December 1996 are reported. Patients were considered to have advanced cancer when receiving only palliative care. Eligibility for HAN was determined by nutritionists applying the following criteria, all of which had to be met: hypophagia, defined as oral calorie intake absent or <50% of basal energy expenditure calculated by the Harris-Benedict formula; life expectancy > 6 weeks, estimated by clinical judgment; suitable patient and family circumstances (pain absent or controlled, no severe vital organ failure, emotional stability, willingness and ability to cope with HAN-related activities and suitable hygienic conditions); and verbal consent obtained after explanation of HAN methods and risks.
Evaluation was done by a nutrition support team (NST) who interviewed patients and family members recording: sex and age, height (cm), actual body weight (kg) and body weight change during the last 6 months; patient awareness of diagnosis; tumour primary site, histological type and metastasis; oral calorie intake; performance status; presence and degree of pain; and presence of vital organ failure. Protein-energy malnutrition was registered when body mass index (kg/m2) was < 20 in males and < 19 in females or there had been a weight loss ) 10% during the past 6 months. Performance status was assessed by the Karnofsky performance status (KPS) scale12 an 11-point rating scale that ranges from normal functioning (100) to dead (0)-and by their ability to go out and look after themselves. Indications for HAN were classified as anorexia, dysphagia and upper or lower gastrointestinal obstruction.
Technique
The NST consisted of a gastroenterologist-nutritionist and trained nurses (one up to 1993, two since 1994), supervised by a gastroenterologist-nutritionist from the local university hospital. The NST had a weekly meeting to evaluate patients' eligibility for HAN and to review patients already on HAN. The mode of access to the gastrointestinal tract (percutaneous endoscopic gastrostomy, jejunostomy, surgi-the NST, if devices were not already present on referral. Nutritional support was calculated for maintaining or improving protein-energy status, serum electrolyte level and urine output. For HEN, commercial solutions were utilized. Solutions for HPN were prepared by the hospital pharmacy up to December 1993. After that, bags containing standard formulas, infusion sets and dressing kits were bought from a specialist firm. Training of patients and/or relatives for HAN management was done at the patient's home whenever possible. Patients and/or relatives were taught all the procedures except central venous catheter dressing, which was always performed by a nurse. Catheter heparinization was avoided by 24-hour HPN infusion whenever this did not limit patient mobility. After the training period, nurses visited patients at home at least once a week taking care of both HAN and matters related to disease. The NST physician visited when HAN-related problems arose, while cancer related medical problems continued to be managed by ANT physicians. 24-hour immediate access to the NST and ANT physicians was available via telephone.
Monitoring
The use of HAN was estimated as incidence and prevalence, respectively calculated as number of new patients per million inhabitants and total days of treatment per year.
Efficacy of HAN was evaluated by: length of survival and cause of death; accuracy of the estimation of expected survival <or > 6 weeks; number, causes and length of hospital readmissions; patients' and families' perception of burdens due to HAN management, categorized by the NST as 'well accepted' (they never complain), 'annoyance' (sometimes complain) or scarcely tolerated (constantly complain); frequency of HAN complications; variations of KPS score and mobility status within the first month of treatment, assessed by the NST physician; and variations of body weight, measured by NST nurses.
Cost analysis was performed on the basis of the number of patients treated from 1 July 1995 to 30 June 1996, only the fixed direct costs of HAN being considered i.e. nutritional formula, infusion lines, dressing kits and salaries of the NST.
Statistics
When appropriate, data are reported as mean (standard deviation). In determining the accuracy of estimation of expected survival < or > 6 weeks, we took into account the length of life of those patients who were not considered eligible for HAN because their predicted survival was <6 weeks13. Statistical differences were evaluated by Student's cal gastrostomy) or the venous circulation was chosen by 598 t-test for unpaired data, X2test and X2 test for trend.
RESULTS
Use of HAN From 1 July 1990 to 30 June 1996, a total of 6838 cancer patients began on the ANT hospital-at-home programme. 587 patients were referred to the NST and 164 (110 males, 54 females; age 65 [14] years) were eligible for HAN (135 enteral and 29 parenteral). Only 50 patients (30%) who received HAN were aware of their diagnosis. In the 423 patients who were not eligible, reasons for exclusion were: absence of hyphophagia in 264, estimated life expectancy < 6 weeks in 108, unsuitable home/family conditions in 30 and lack of consent in 21. The use of HAN is reported in Table 1 . The incidence doubled from the first to the third year of activity then appeared stable, whereas the total days of treatment increased constantly through the years. The clinical characteristics of patients on starting HAN are shown in Table 2 . 60% of patients had metastases, 40% had local advanced disease. 13 patients on HEN (8%) were able to go out and to look after themselves unaided; the remaining 151 were housebound.
For HEN the access route was nasogastric tube in 50% of patients, percutaneous endoscopic gastrostomy in 18%, jejunostomy in 27%, and surgical gastrostomy in 5%; training, performed at the patient's home in 64% of cases and before hospital discharge in 36%, was given to patients in 11% of cases and to relatives in 89%; infusion was by pump in 83% of cases and by gravity in 17% and was always cyclical (diurnal or nocturnal). For HPN, access was by non-tunnelled percutaneous catheters in 79% of cases, tunnelled percutaneous catheters in 14% and totally implanted ports in 7%; training was at the patient's home and given to relatives in all the cases; infusion, always by gravity, was cyclical in 31% of cases and continuous in 69%.
Efficacy
On 31 December 1996, 158 patients (130 HEN, 28 HPN) had died because of their disease and 6 (5 HEN and 1 HPN) were still on treatment ( Figure 1 ). Mean survival was 17.2 (19.5) weeks for those on HEN and 12.2 (8.0) weeks for those on HPN. The duration of life in patients grouped for characteristics on starting HAN and for the year of entry into the study is reported in Table 3 . 47 (29%) patients survived <6 weeks. The percentage of those living <6 weeks was greater in the groups with a primary tumour located outside the gastrointestinal tract and the head-neck region and in the group with a KPS score > 40. The proportion surviving < 6 weeks decreased during the first 3 (20) , stomach (46), large bowel (13) tovary (4) , kidney (2) .pancreas (6) , bone (3), skin (2), breast (2), brain (3) 18 for palliative radiation or chemotherapy, 7 for jejunostomy positioning and 127 for the underlying disease. 88 readmissions (in 59 patients) were followed by a return to HAN and 67 were followed by death (13 HPN and 54 HEN). The percentage of patients who were readmitted to hospital as well as the number and the total days of readmission per patient increased in parallel with duration of survival. No significant difference was observed Burdens for patient and family due to HAN management were judged 'well accepted' in 124 cases (39 aware of diagnosis, 19 HPN), an 'annoyance' in 30 (9 aware of diagnosis, 7 HPN) and 'scarcely tolerated' in 10 (1 aware of diagnosis, 3 HPN). The frequency of nasogastric tube blockage was 0.26 per year of HEN and that of dislodgment was the same. The percutaneous endoscopic gastroscopy site became infected in 1 patient and 2 required hub replacement. Frequency of complications per year of HPN was 0.67 for catheter sepsis, 0.16 for deep vein thrombosis and 0.50 for metabolic instability. During the first month of HAN, the KPS score increased (+ 11.5 [3.6] of these patients the potential yearly incidence of HAN would be three times greater than we observed-that is, about 80 HEN and 40 HPN per million inhabitants. These figures are many times greater than those reported by the Italian registers (1.24 for HPN and 6.8 for HEN)5'15 and by the other European registers2+46, but resemble those observed in the USA7 where the yearly prevalence of HPN is about 120 and that of HEN is 415 per million population (40% for cancer patients). How effective was HAN in preventing death from cachexia? This judgment depended on clinical estimation of life expectancy, which was 72% accurate. Estimation of survival is a critical point in the decision-making process of starting HAN in advanced cancer. We considered patients at risk of death from cachexia if they had hypophagia and life expectancy > 6 weeks. In healthy individuals loss of lean body mass becomes incompatible with life after 2-3 months of starvation16. When we corrected for the expected presence of malnutrition and increased nitrogen catabolism due to the cancer, we thought 6 weeks an acceptable period. Analysis of the single years showed a learning curve over the first 3 years of follow-up for prediction of survival ., 6 weeks but no improvement for prediction of survival <6 weeks. Several clinical and nutritional indices have been used to estimate prognosis in cancer patients but none seems to work well17. The best results were obtained by Bruera et al.18 , who observed that cognitive failure, dysphagia and weight loss of 10kg were independently associated with poor prognosis and in a given patient predicted survival of <4 weeks with an accuracy of 74%.
HAN was effective in maintaining patients at home without causing additional burdens to patient and family but improved the performance status in only a few cases. Hospital readmission occurred in 61% of patients who spent 15-23% of their survival time in hospital, with a mean of 1.6 episodes per patient, mainly due to the cancer Key elements for the decision were defined as the oncological and clinical condition, the expected survival (estimated by clinical judgment as more or less than 2 months), hydration and nutrition status, symptoms, oral nutrient intake (more or less than 75% of basal energy expenditure), patient's psychological attitude, gut function and the route for giving nutrients and water and health service availability to provide nutrition. Our criteria for evaluating patient eligibility seem to fit well with these guidelines.
The daily fixed direct cost of HAN was about 32.4 ECU for HEN and 75.2 ECU for HPN. A complete evaluation of costs must also consider the access route device and its positioning, laboratory tests, management of complications and administrative costs10. Furthermore, the costs due to the hospital-at-home programme must be considered.
Preliminary data on cost analysis of ANT assistance for patients receiving neither HAN nor chemotherapy, including fixed costs (staff salaries, physiotherapy, patient and health professional transport, overhead costs and loss of income by family members due to commitments at home) and variable costs (family doctor, laboratory, radiology and drugs) gave a daily amount of about 53 ECU per patienttwo-thirds lower than hospital costs22.
Summarizing our 6 year prospective study, we conclude that (a) definite entry criteria and local surveys are required for the correct planning of HAN use; (b) HAN can maintain patients at home without causing additional burdens and distress to patient and family; (c) this health technology can be offered at home with the combined efforts of patient and family for costs that are not obviously higher than hospital costs.
